Condition: B-Cell Acute Lymphoblastic Leukemia, Adult · Sponsor: The First Affiliated Hospital of Soochow University
This clinical trial aims to investigate the safety, optimal dosage, and effectiveness of allogeneic CD19-targeted CAR-γδT Cell in treating CD19-positive relapsed/refractory B-ALL
This description comes directly from the study's public registry record.
Xiaowen Tang, Ph.D · (0086)051267780086 · xwtang1020@163.com
Depei Wu, Ph.D · (0086)051267780086 · drwudepei@163.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Soochow University | Suzhou, China, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06696833